The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.
A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no ...
A new study from Huashan Hospital, Shanghai, provided strong evidence supporting the efficacy and safety of abrocitinib for ...
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...
As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback